KRYS - Krystal Biotech, Inc.
| Previous Close | 22.27 |
| Open | 22.31 |
| Bid | 21.00 x 900 |
| Ask | 24.00 x 1100 |
| Day's Range | 21.91 - 23.45 |
| 52 Week Range | 8.61 - 28.75 |
| Volume | 33,476 |
| Avg. Volume | 46,547 |
| Market Cap | 331.72M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.25 |
- American City Business Journals•28 days ago
Danforth Advisors entering Pittsburgh, focusing on life sciences sector
Danforth Advisors, a Boston-area provider of financial and accounting services to the life sciences sector, has entered Pittsburgh. Founded in 2011, Danforth employs a team of consultants who are experienced accountants, corporate controllers and chief financial officers and specialists in financial planning and analysis. “Biotech companies are often pre-revenue stage and trying to build a business focused on science and getting things into the clinics,” said Robert Dickey IV, who joined Danforth last summer as managing director, Mid-Atlantic Region.
- GlobeNewswire•last month
Krystal Biotech Completes Construction of Ancoris - A New GMP Facility for Commercial Manufacturing of a Viral Vector-Based Gene Therapy to Treat Dystrophic Epidermolysis Bullosa
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that construction of Ancoris, a new state-of-the-art Good Manufacturing Practice (GMP) facility, is complete. The new facility is located near the Company’s headquarters in Pittsburgh and will support clinical and commercial manufacturing of Krystal’s lead product candidate, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). “Our development of internal manufacturing capabilities bolsters our position for commercial readiness as we execute on our vision to bring our therapies to the patient communities in need,” said Krish S Krishnan, chairman and chief executive officer of Krystal Biotech.
- GlobeNewswire•2 months ago
Krystal Biotech Completes Dosing in the GEM-Phase 2 Study in Pediatric Patients for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, Dec. 19, 2018 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare.
- GlobeNewswire•3 months ago
New Research Coverage Highlights VSE, Weyco Group, Funko, B. Riley Financial, Krystal Biotech, and Xcel Brands — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•3 months ago
Krystal Biotech to Present at Evercore ISI HealthCONx
PITTSBURGH, Nov. 20, 2018 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients.
- GuruFocus.com•4 months ago
Krystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $500,000 of Shares
President and CEO of Krystal Biotech Inc (NASDAQ:KRYS) Krish S Krishnan bought 25,000 shares of KRYS on 10/18/2018 at an average price of $20 a share.
- PR Newswire•4 months ago
Chardan Serves as Lead Manager for Krystal Biotech
NEW YORK , Oct. 22, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced that the firm is acting as lead manager in the follow-on offering for Krystal Biotech, Inc. (NASDAQ: KRYS), a gene ...
- PR Newswire•6 months ago
Chardan Capital Markets acts as Sole Placement Agent in $10 Million Securities Purchase
NEW YORK , Aug. 17, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as sole placement agent in Krystal Biotech, Inc.'s (NASDAQ: KRYS) securities purchase agreement ...
- Zacks•7 months ago
Krystal Biotech (KRYS) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).
- Zacks•8 months ago
Can the Rally in Krystal Biotech (KRYS) Shares Continue?
Krystal Biotech, Inc. (KRYS) has been on the move lately as the stock has risen by 24.5% in the past four weeks, and it is currently trading well above its 20-Day SMA
- ACCESSWIRE•9 months ago
Blog Exposure - Krystal Biotech’s KB103 Granted Fast Track Designation by FDA for Treatment of Dystrophic Epidermolysis Bullosa
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Krystal Biotech, Inc. (NASDAQ: KRYS) ("Krystal"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KRYS as the Company's latest news hit the wire. On May 24, 2018, the Pennsylvania-based Company announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the Company's lead product, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). KB103 is the first-ever topically-applied herpes simplex virus (HSV-1) based gene therapy engineered to deliver a human collagen protein to patients suffering from DEB.
